Is SYRE or VERA more profitable?

Spyre Therapeutics' return on equity of -30.74% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -30.74% -22.23% Vera Therapeutics N/A -84.13% -66.79%

Does the media refer more to SYRE or VERA?

In the previous week, Vera Therapeutics had 3 more articles in the media than Spyre Therapeutics. MarketBeat recorded 8 mentions for Vera Therapeutics and 5 mentions for Spyre Therapeutics. Vera Therapeutics' average media sentiment score of 0.58 beat Spyre Therapeutics' score of 0.43 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vera Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, IMVT or VERA?

Immunovant is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.82 N/A Vera Therapeutics N/A N/A -$299.61M -$5.86 N/A

Is IMVT or VERA more profitable?

Immunovant's return on equity of -69.59% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% Vera Therapeutics N/A -84.13% -66.79%

Does the media refer more to IMVT or VERA?

In the previous week, Immunovant and Immunovant both had 8 articles in the media. Immunovant's average media sentiment score of 0.97 beat Vera Therapeutics' score of 0.58 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, VERA or PCVX?

Vaxcyte is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vera Therapeutics N/A N/A -$299.61M -$5.86 N/A Vaxcyte N/A N/A -$766.63M -$7.63 N/A

Is VERA or PCVX more profitable?

Vaxcyte's return on equity of -37.56% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vera Therapeutics N/A -84.13% -66.79% Vaxcyte N/A -37.56% -33.62%

Does the media prefer VERA or PCVX?

In the previous week, Vera Therapeutics had 4 more articles in the media than Vaxcyte. MarketBeat recorded 8 mentions for Vera Therapeutics and 4 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.07 beat Vera Therapeutics' score of 0.58 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, APGE or VERA?

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apogee Therapeutics N/A N/A -$255.84M -$4.34 N/A Vera Therapeutics N/A N/A -$299.61M -$5.86 N/A

Is APGE or VERA more profitable?

Apogee Therapeutics' return on equity of -29.88% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Apogee Therapeutics N/A -29.88% -28.08% Vera Therapeutics N/A -84.13% -66.79%

Does the media favor APGE or VERA?

In the previous week, Vera Therapeutics had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 8 mentions for Vera Therapeutics and 5 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.39 beat Vera Therapeutics' score of 0.58 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ALKS or VERA?

In the previous week, Vera Therapeutics had 4 more articles in the media than Alkermes. MarketBeat recorded 8 mentions for Vera Therapeutics and 4 mentions for Alkermes. Alkermes' average media sentiment score of 1.02 beat Vera Therapeutics' score of 0.58 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vera Therapeutics (VERA) Competitors

$32.28 +1.02 (+3.26%)

As of 08/21/2026 04:00 PM Eastern

Compare

VERA vs. SYRE, IMVT, PCVX, APGE, and ALKS

Should you buy Vera Therapeutics stock or one of its competitors? Vera Therapeutics's main competitors and comparable companies include Spyre Therapeutics (SYRE), Immunovant (IMVT), Vaxcyte (PCVX), Apogee Therapeutics (APGE), and Alkermes (ALKS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vera Therapeutics compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Vera Therapeutics had 3 more articles in the media than Spyre Therapeutics. MarketBeat recorded 8 mentions for Vera Therapeutics and 5 mentions for Spyre Therapeutics. Vera Therapeutics' average media sentiment score of 0.58 beat Spyre Therapeutics' score of 0.43 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vera Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics currently has a consensus target price of $111.69, suggesting a potential upside of 4.89%. Vera Therapeutics has a consensus target price of $81.15, suggesting a potential upside of 151.41%. Given Vera Therapeutics' higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Spyre Therapeutics' return on equity of -30.74% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Vera Therapeutics	N/A	-84.13%	-66.79%

Spyre Therapeutics has higher revenue and earnings than Vera Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	10,522.17	-$155.20M	-$1.95	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A

Spyre Therapeutics has a beta of 3.03, suggesting that its share price is 203% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

Summary

Spyre Therapeutics beats Vera Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Vera Therapeutics compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 1.9% of Immunovant shares are owned by insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Immunovant's return on equity of -69.59% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Vera Therapeutics	N/A	-84.13%	-66.79%

Immunovant is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A

Immunovant has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

In the previous week, Immunovant and Immunovant both had 8 articles in the media. Immunovant's average media sentiment score of 0.97 beat Vera Therapeutics' score of 0.58 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant presently has a consensus price target of $44.00, suggesting a potential downside of 0.83%. Vera Therapeutics has a consensus price target of $81.15, suggesting a potential upside of 151.41%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vera Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Vera Therapeutics beats Immunovant on 9 of the 13 factors compared between the two stocks.

How does Vera Therapeutics compare to Vaxcyte?

Vera Therapeutics (NASDAQ:VERA) and Vaxcyte (NASDAQ:PCVX) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

In the previous week, Vera Therapeutics had 4 more articles in the media than Vaxcyte. MarketBeat recorded 8 mentions for Vera Therapeutics and 4 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.07 beat Vera Therapeutics' score of 0.58 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vera Therapeutics presently has a consensus price target of $81.15, indicating a potential upside of 151.41%. Vaxcyte has a consensus price target of $86.00, indicating a potential upside of 37.34%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Vera Therapeutics is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Vera Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

Vaxcyte's return on equity of -37.56% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-84.13%	-66.79%
Vaxcyte	N/A	-37.56%	-33.62%

99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by company insiders. Comparatively, 3.3% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Vaxcyte is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

Summary

Vera Therapeutics beats Vaxcyte on 10 of the 14 factors compared between the two stocks.

How does Vera Therapeutics compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Apogee Therapeutics has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

Apogee Therapeutics' return on equity of -29.88% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-29.88%	-28.08%
Vera Therapeutics	N/A	-84.13%	-66.79%

Apogee Therapeutics presently has a consensus target price of $124.43, indicating a potential downside of 7.66%. Vera Therapeutics has a consensus target price of $81.15, indicating a potential upside of 151.41%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vera Therapeutics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.20
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Vera Therapeutics had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 8 mentions for Vera Therapeutics and 5 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.39 beat Vera Therapeutics' score of 0.58 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A

Summary

Vera Therapeutics beats Apogee Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Vera Therapeutics compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Alkermes has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

In the previous week, Vera Therapeutics had 4 more articles in the media than Alkermes. MarketBeat recorded 8 mentions for Vera Therapeutics and 4 mentions for Alkermes. Alkermes' average media sentiment score of 1.02 beat Vera Therapeutics' score of 0.58 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Alkermes has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	5.49	$241.66M	$0.38	127.18
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A

Alkermes has a net margin of 3.96% compared to Vera Therapeutics' net margin of 0.00%. Alkermes' return on equity of 4.15% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Vera Therapeutics	N/A	-84.13%	-66.79%

Alkermes currently has a consensus price target of $54.56, indicating a potential upside of 12.90%. Vera Therapeutics has a consensus price target of $81.15, indicating a potential upside of 151.41%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Vera Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Alkermes beats Vera Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Vera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERA vs. The Competition

Export

Metric	Vera Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.33B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-5.51	11.62	272.60	24.24
Price / Sales	N/A	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	5.70	16.80	13.05	6.20
Net Income	-$299.61M	-$12.50M	$3.47B	$348.59M
7 Day Performance	2.06%	3.29%	2.09%	0.08%
1 Month Performance	-11.20%	8.23%	6.64%	3.88%
1 Year Performance	43.02%	55.05%	25.02%	16.98%

Vera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERA Vera Therapeutics	3.1168 of 5 stars	$32.28 +3.3%	$81.15 +151.4%	+43.0%	$2.33B	N/A	N/A	40
SYRE Spyre Therapeutics	1.5009 of 5 stars	$104.60 +0.9%	$111.69 +6.8%	+512.7%	$9.11B	N/A	N/A	73
IMVT Immunovant	1.4326 of 5 stars	$43.71 +4.5%	$44.00 +0.7%	+191.1%	$9.03B	N/A	N/A	120
PCVX Vaxcyte	2.2532 of 5 stars	$60.22 +3.7%	$86.00 +42.8%	+93.9%	$8.64B	N/A	N/A	160	Positive News
APGE Apogee Therapeutics	1.3679 of 5 stars	$134.59 +0.0%	$124.43 -7.5%	+252.1%	$8.37B	N/A	N/A	91	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERA) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vera Therapeutics (VERA) Competitors

VERA vs. SYRE, IMVT, PCVX, APGE, and ALKS

How does Vera Therapeutics compare to Spyre Therapeutics?

Summary

How does Vera Therapeutics compare to Immunovant?

Summary

How does Vera Therapeutics compare to Vaxcyte?

Summary

How does Vera Therapeutics compare to Apogee Therapeutics?

Summary

How does Vera Therapeutics compare to Alkermes?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERA vs. The Competition

Vera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vera Therapeutics (VERA) Competitors

VERA vs. SYRE, IMVT, PCVX, APGE, and ALKS

How does Vera Therapeutics compare to Spyre Therapeutics?

Do institutionals and insiders hold more shares of SYRE or VERA?

Does the media refer more to SYRE or VERA?

Do analysts prefer SYRE or VERA?

Is SYRE or VERA more profitable?

Which has preferable valuation & earnings, SYRE or VERA?

Which has more risk & volatility, SYRE or VERA?

Summary

How does Vera Therapeutics compare to Immunovant?

Do institutionals and insiders hold more shares of IMVT or VERA?

Is IMVT or VERA more profitable?

Which has stronger earnings & valuation, IMVT or VERA?

Which has more volatility & risk, IMVT or VERA?

Does the media refer more to IMVT or VERA?

Do analysts recommend IMVT or VERA?

Summary

How does Vera Therapeutics compare to Vaxcyte?

Does the media prefer VERA or PCVX?

Do analysts recommend VERA or PCVX?

Which has more volatility and risk, VERA or PCVX?

Is VERA or PCVX more profitable?

Do insiders & institutionals believe in VERA or PCVX?

Which has better earnings & valuation, VERA or PCVX?

Summary

How does Vera Therapeutics compare to Apogee Therapeutics?

Which has more risk & volatility, APGE or VERA?

Is APGE or VERA more profitable?

Do analysts recommend APGE or VERA?

Do insiders and institutionals believe in APGE or VERA?

Does the media favor APGE or VERA?

Which has better valuation & earnings, APGE or VERA?

Summary

How does Vera Therapeutics compare to Alkermes?

Which has more risk and volatility, ALKS or VERA?

Does the media refer more to ALKS or VERA?

Do institutionals & insiders believe in ALKS or VERA?

Which has higher earnings and valuation, ALKS or VERA?

Is ALKS or VERA more profitable?

Do analysts prefer ALKS or VERA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERA vs. The Competition

Vera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools